Cargando…

Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas

Background Despite improved screening techniques, diagnosis of lung cancer is often late and its prognosis is poor. In the present study, in vitro chemosensitivity of solid tumours and pleural effusions of lung adenocarcinomas were analysed and compared with clinical drug response. Methods Tumour ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Emoke, Steib, Anita, Abdelwahab, Elhusseiny MM, Meggyes-Rapp, Judit, Jakab, Laszlo, Smuk, Gabor, Schlegl, Erzsebet, Moldvay, Judit, Sárosi, Veronika, Pongracz, Judit E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292226/
https://www.ncbi.nlm.nih.gov/pubmed/32527872
http://dx.doi.org/10.1136/bmjresp-2019-000505
_version_ 1783546066602295296
author Papp, Emoke
Steib, Anita
Abdelwahab, Elhusseiny MM
Meggyes-Rapp, Judit
Jakab, Laszlo
Smuk, Gabor
Schlegl, Erzsebet
Moldvay, Judit
Sárosi, Veronika
Pongracz, Judit E
author_facet Papp, Emoke
Steib, Anita
Abdelwahab, Elhusseiny MM
Meggyes-Rapp, Judit
Jakab, Laszlo
Smuk, Gabor
Schlegl, Erzsebet
Moldvay, Judit
Sárosi, Veronika
Pongracz, Judit E
author_sort Papp, Emoke
collection PubMed
description Background Despite improved screening techniques, diagnosis of lung cancer is often late and its prognosis is poor. In the present study, in vitro chemosensitivity of solid tumours and pleural effusions of lung adenocarcinomas were analysed and compared with clinical drug response. Methods Tumour cells were isolated from resected solid tumours or pleural effusions, and cryopreserved. Three-dimensional (3D) tissue aggregate cultures were set up when the oncoteam reached therapy decision for individual patients. The aggregates were then treated with the selected drug or drug combination and in vitro chemosensitivity was tested individually measuring ATP levels. The clinical response to therapy was assessed by standard clinical evaluation over an 18 months period. Results Based on the data, the in vitro chemosensitivity test results correlate well with clinical treatment response. Conclusions Such tests if implemented into the clinical decision making process might allow the selection of an even more individualised chemotherapy protocol which could lead to better therapy response.
format Online
Article
Text
id pubmed-7292226
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-72922262020-06-16 Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas Papp, Emoke Steib, Anita Abdelwahab, Elhusseiny MM Meggyes-Rapp, Judit Jakab, Laszlo Smuk, Gabor Schlegl, Erzsebet Moldvay, Judit Sárosi, Veronika Pongracz, Judit E BMJ Open Respir Res Lung Cancer Background Despite improved screening techniques, diagnosis of lung cancer is often late and its prognosis is poor. In the present study, in vitro chemosensitivity of solid tumours and pleural effusions of lung adenocarcinomas were analysed and compared with clinical drug response. Methods Tumour cells were isolated from resected solid tumours or pleural effusions, and cryopreserved. Three-dimensional (3D) tissue aggregate cultures were set up when the oncoteam reached therapy decision for individual patients. The aggregates were then treated with the selected drug or drug combination and in vitro chemosensitivity was tested individually measuring ATP levels. The clinical response to therapy was assessed by standard clinical evaluation over an 18 months period. Results Based on the data, the in vitro chemosensitivity test results correlate well with clinical treatment response. Conclusions Such tests if implemented into the clinical decision making process might allow the selection of an even more individualised chemotherapy protocol which could lead to better therapy response. BMJ Publishing Group 2020-06-10 /pmc/articles/PMC7292226/ /pubmed/32527872 http://dx.doi.org/10.1136/bmjresp-2019-000505 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Lung Cancer
Papp, Emoke
Steib, Anita
Abdelwahab, Elhusseiny MM
Meggyes-Rapp, Judit
Jakab, Laszlo
Smuk, Gabor
Schlegl, Erzsebet
Moldvay, Judit
Sárosi, Veronika
Pongracz, Judit E
Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
title Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
title_full Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
title_fullStr Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
title_full_unstemmed Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
title_short Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
title_sort feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
topic Lung Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292226/
https://www.ncbi.nlm.nih.gov/pubmed/32527872
http://dx.doi.org/10.1136/bmjresp-2019-000505
work_keys_str_mv AT pappemoke feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas
AT steibanita feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas
AT abdelwahabelhusseinymm feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas
AT meggyesrappjudit feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas
AT jakablaszlo feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas
AT smukgabor feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas
AT schleglerzsebet feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas
AT moldvayjudit feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas
AT sarosiveronika feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas
AT pongraczjudite feasibilitystudyofinvitrodrugsensitivityassayofadvancednonsmallcelllungadenocarcinomas